

NEXT SCIENCE®

2022 Half Year Results Investor Briefing

Sydney, Australia, Thursday, 11 August 2022: Next Science Limited (ASX:NXS) advises that it intends to release its results for the half year ended 30 June 2022 on Thursday, 25 August 2022.

Next Science's Managing Director, Judith Mitchell, will host an investor conference call and webcast at **10.00am** (Sydney time) on **Thursday, 25 August 2022** to discuss the results. The briefing is expected to last approximately 45 minutes inclusive of question time.

To pre-register for the call, please use the following link:

<https://s1.c-conf.com/diamondpass/10023280-te3t21.html>

To register to participate via webcast, please use the following link:

<https://webcast.openbriefing.com/8958/>

Approved and authorised by Judith Mitchell, Managing Director, Next Science Limited.

Further information:

Judith Mitchell

Managing Director, Next Science Limited

Phone: +61 2 8607 5124

Email: investorqueries@nextscience.com

Michael Brown

Pegasus Advisory

Phone: +61 400 248 080

Email: mbrown@pegasusadvisory.com.au

About Next Science

Next Science is a medical technology company headquartered in Sydney, Australia, with a research and development centre in Florida, USA. Established in 2012, the Company's primary focus is on the development and commercialisation of its proprietary Xbio™ technology to reduce the impact of biofilm based infections in human health. Xbio is a unique, non-toxic technology with proven efficacy in eradicating both biofilm based and free-floating bacteria. Next Science owns 100% of the patent protected intellectual property relating to its Xbio technology. Website: www.nextscience.com.